NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL

CompletedN/A

Sponsor: AstraZeneca

Conditions: Diffuse Large B Cell Lymphoma

Countries: Brazil

National, multicenter, non-randomized, retrospective observational study (Real World Evidence-RWE) to analyze the epidemiological profile of diffuse large B cell lymphoma, clinical management, treatment in molecular subgroups, progression profile and patient survival outcomes enrolled and treated within the last 6 years (2017 to 2022), in national cancer reference centers.

Eligibility overview

Sex: ALL

Age: 18 Years to 100 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Male and female;
* Age above 18 years old;
* Diagnosis of diffuse large B-cell lymphoma (DLBCL) and high-grade non-Hodgkin B-cell lymphoma at all stagings;
* Lymphoma classified for the cell of origin (GCB - Germinal Center B-Cell lymphoma, and non-germinal center);
* Having first life of treatment information available in institutional medical record;
* Having survival data available in institutional medical record.

Exclusion Criteria:

* No medical record of the molecular subgroup classification;
* Diagnosis of diffuse large B-cell lymphoma, confirmed in the year 2016;
* Patients diagnosed with Transformed Lymphomas.

Locations (4)

Belo Horizonte, Brazil
Recife, Brazil
Salvador, Brazil
São Paulo, Brazil